It’s February 7thand the medical community is observing Congenital Heart Defect Awareness Week sponsored by the American Heart Association to encourage awareness and education about congenital heart defects (CHDs). This week has been set aside to honor those born with a heart defect and all of the families and friends touched by children with heart defects. As participants of multiple CHD trials and validation studies lets discuss CHD challenges and solutions for rapid CHD detection.
According to the American Heart Association, about one child out of 100 births every year in the US is born with a CHD condition. This is due to a problem that happens as the child’s heart is developing during pregnancy, before the child is born. CHDs are the most common type of birth defects and people live with heart defects throughout their lives. As we all know, there are many types of congenital heart defects and the most common involve the inside walls of the heart, the valves of the heart, or the large blood arteries and veins carrying blood to and from the heart. Some of these heart defects require no treatment; however others require treatment soon after birth. Treatments which have many dependencies can include medications, catheter procedures, surgery, and sometimes heart transplants. Because cardiac diagnosis and treatment has greatly improved, more children are surviving and many CHD adults are living full complete lives.
Regardless of treatment, detection and monitoring are key for managing CHD; the gold standard has been ultrasound echocardiogram, however recent clinical studies in India have validated that new EKG-enabled intelligent stethoscope technology can serve as a precursor to ultrasound echocardiogram for CHD detection and monitoring.
This new technology solution which integrates digital auscultation with EKG functionality and diagnostic imaging in the familiar shape and size of a stethoscope is called HD Steth. HD Steth leverages digital health technologies to instantly detect and diagnose CHD. This represents a paradigm shift at the point-of-care setting. Now medical professionals can instantly identify a patient’s cardiac condition, capture and share patient data, and identify cardiac defects in real-time improving patient quality-of-life.
Care for and monitoring of cardiac diseases is a major challenge for the health community. Currently thirty eight percent (38%) of deaths worldwide are attributable to cardiac disease and the associated cost of cardiac disease management is exceeding $1T per year. Exasperating the situation, the ratio of population to specialists is in the range of 10,000 to 1 in the USA (higher elsewhere) creating challenges in making critical clinical decisions during the “golden hour” of a cardiac event.
Additionally, according to Dr. Nelson B. Schiller, MD, FACC, FRCP “Standardized auscultation tests given to medical students and fellows have found auscultation is either not taught well enough or students have difficulty learning it. Results show that only 30% of medical students tested are able to detect typical heart sounds and murmurs versus the internal medicine residents getting up to 40% while Fellows reach into the 50 -60% range.” In addition, according to Dr. Paul Rosen in his recent HealthcareSuccess.com blog “At the medical school at Stanford University, 35 percent of graduating students are forgoing residency training and taking jobs in start-ups instead. The cultures they see outside of health systems resonate more with their values.” Also, according to Rosen “in the area of patient safety, over 400,000 deaths in hospitals are due to medical errors each year, making medical errors the 3rd leading cause of death in the Unites States.”
These challenges are being overcome with recent advances in medical imaging along with increased computational power and the advent of mobility, wireless and other technologies. This now allows patients to be treated and monitored more precisely and effectively and in ways that better meet their individual needs.
HD Medical’s HD Steth comes at a perfect inflection point as healthcare is shifting and focusing on wellness and prevention rather than treating patients after an incident.
– New ViScope Telemedicine Software will be Showcased –
Chicago, IL – April 13, 2015 – At HiMSS 15, HD Medical, Inc. demonstrates the new ViScope® visual stethoscope product family. These unique visual stethoscopes provide “dynamic auscultation™”, the ability to see what you hear. ViScope’s integrated visual display shows heart waveforms in real-time making it a perfect device for patient screening, teaching and telemedicine. HD Medical will showcase the new ViScope Telemedicine Software at the show this week. ViScope records patient heart anomalies so medical professionals can share with colleagues, students, insurance companies and electronic medical records.
The ViScope visual display is complemented by high fidelity sound quality and amplification up to 30 times louder than a traditional scope for unmatched clarity. HD Medical has invested over a decade refining its proprietary noise reduction technology.
ViScope also records patient heart sounds for 10 seconds capturing the first heart sounds, often the most telling for healthcare professionals. The scope’s heart sound recordings can be transferred to a PC configured with the ViScope bundled software to access a tunable filter that provides the ability to select specific parts of the heart sound to listen to, such as S1/S2, S3/S4, etc. ViScope’s value as a screening tool for early detection of cardiac defects has been validated through multiple clinical trials.
ViScope product family includes:
“HD Medical’s visual stethoscopes are uniquely capable of addressing today’s evidence based medical environment,” states Arvind Thiagarajan, Chairman and Chief Inventor for HD Medical. “ViScope is the industry’s first stethoscope to enable documentation of heart data which can be used for patient reporting and analysis as well as information sharing, teaching situations and telemedicine applications.”
ViScope has been awarded the US Food and Drug Administration (FDA) 510 (K) clearance and is CE compliant. ViScope is sold from the website and through HD Medical’s network of resellers in the USA.
~ Support Program Delivers Significant Channel Advantages for Unique Visual Stethoscope ~
Sunnyvale, CA – July 28, 2014 – Amidst growing distributor, partner and OEM demand for its new visual stethoscope, ViScope®, HD Medical, Inc. launches its new “Channel Advantage™” program. The philosophy behind Channel Advantage is to position HD Medical as business partner and revenue generator for these business relationships. Channel Advantage is multi-faceted ranging from value based pricing and integration support to providing qualified leads and marketing resources as well as achievement awards and discount models among other advantages.
“HD Medical is dedicated to channel success, giving corporate priority to the realization of a robust resource base they can call upon,” said Muthu Krishnan, HD Medical’s Senior Vice President of Business Development. “Channel Advantage targets distributors, partners and OEMs worldwide in the wake of huge sales successes internationally including a multi-million dollar order from the Government of India. Channel Advantage serves as the catalyst to make sales happen for these strategic relationships.”
With ViScope, HD Medical pioneers the concept of the state-of-the-art visual stethoscope offering a unique integrated high resolution visual display. ViScope provides better functionality with high definition sound quality and the ability to “see what you hear” for “dynamic auscultation™”. ViScope is used by cardiologists, general practitioners, nurses, paramedics and other medical professionals in private practice, hospitals and clinics. Of significance, ViScope records and documents heart anomalies for today’s evidence-based world, enabling it to serve as a stethoscope modality for electronic medical records (EMR). Additionally, ViScope performs remote patient monitoring supporting telemedicine applications for rapid patient screenings.
ViScope has received the US Food and Drug Administration (FDA) 510 (K) clearance and CE certification. Distributors, partners and OEMs wishing to discuss relationships and the Channel Advantage program further should contact Muthu Krishnan, mobile: 408-483-8506, email: firstname.lastname@example.org